http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#Head
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#assertion
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#provenance
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#pubinfo
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#assertion
http://purl.obolibrary.org/obo/DOID_10763
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10763
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00177
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
http://www.w3.org/2000/01/rdf-schema#label
prexxartan is an angiotensin ii receptor blocker arb indicated for hypertension in adults and children six years and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1 1 heart failure nyha class ii iv prexxartan significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets 1 2 stable left ventricular failure or left ventricular dysfunction following myocardial infarction prexxartan reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets 1 3 prexxartan is indicated for the treatment of hypertension in adults and children six years and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension e g patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy prexxartan may be used alone or in combination with other antihypertensive agents prexxartan is indicated for the treatment of heart failure nyha class ii iv to reduce the risk of hospitalization for heart failure in patients who are unable to swallow valsartan tablets there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor see warnings and precautions 5 2 clinical pharmacology 12 3 clinical studies 14 2 prexxartan is indicated to reduce the risk of cardiovascular death in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction who are unable to swallow valsartan tablets see warnings and precautions 5 2 clinical pharmacology 12 3 clinical studies 14 3
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00177
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#provenance
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#pubinfo
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#sig
http://purl.org/nanopub/x/hasSignature
GO6AnGrrPLKHGk78qN7YEsUK+VFaC2NCvEEDaYlosIhm2YDw7b9TuvnNhFNi4x7NXJg3fAhqQzH6LS3EWNdSnbleqA28GDaRlrtiDJofrWlf4Gi1s+EXdj3LpTJIA+1SROslpOq5MRAlqKgIJp16FauW21Lk/XyPT8G+QqxSr3E=
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://purl.org/dc/terms/created
2021-06-27T20:03:15.009+02:00
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RABiFx522ypV1koZ5Qso7g75w2vKMqJr_dnJdTfDY32ro
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs